Welcome to LasikEyeSurgery
| Before and After | Lasik Risks | Lasik Definitions | FAQs
| Resources | Disclaimer
Updates on Lasik Eye Surgery In Ma
EyeGate Pharma Announces That EGP-437 Improved Signs And Symptoms Of Dry Eye Syndrome In A Phase II Study (Medical News Today)
Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES). For the dry eye clinical trial, EyeGate worked with Ora, Inc., a leading global clinical research and development organization located in Andover, MA.
Read more...EyeGate Pharma Announces That EGP-437 Improved Signs and Symptoms of Dry Eye Syndrome in a Phase II Study (Marketwire)
WALTHAM, MA--(Marketwire - June 3, 2009) - Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES). For the dry eye clinical trial, EyeGate worked with Ora, Inc., a leading global clinical research and ...
Read more...